Gustavo Henrique Corrêa Soares

Gustavo Henrique Corrêa Soares

Auto-generated profile, based on publicly available information

Gustavo Henrique Corrêa Soares

Department of Biology, Federal University of Maranhão, São Luís, Brazil

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2020 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
GSGustavo Henrique Corrêa Soares
Gustavo Henrique Corrêa Soares
ASAndrea Beatrice Santos da Silva
Andrea Beatrice Santos da Silva
LFLucas Salomão de Sousa Ferreira
Lucas Salomão de Sousa Ferreira
JIJorim Severino Ithamar
Jorim Severino Ithamar
GMGuilherme de Alencar Medeiros
Guilherme de Alencar Medeiros
CAConceição de Maria Pedrozo e Silva Azevedo
Conceição de Maria Pedrozo e Silva Azevedo
Diffuse cutaneous leishmaniasis (DCL) is a rare type of leishmaniasis characterized by diffuse skin lesions. In Brazil, Leishmania (L.) amazonensis is the main etiological agent of this clinical form. The state of Maranhão has the highest prevalence of this disease in the country, as well as a high rate of HIV infection. Here, we report the first case of DCL/HIV of Brazil. A 46-year-old man from the Amazonian area of Maranhão state presented atypical lesion in the left upper limb and dissemination of diffuse erythematous nodules over his entire body. Histopathological examination confirmed the presence of intracellular amastigotes of Leishmania, and a polymerase chain reaction and molecular identification by restriction fragment profile identified L. (L.) amazonensis as the causative agent of the disease. The patient was also diagnosed with HIV virus after the leishmaniasis diagnosis. The initial treatments for leishmaniasis were liposomal amphotericin B (AmB-L) (4 mg/kg) for 10 days and prophylactic use of Glucantime® (10 mg/Sb+5/kg) for 2 months. After unsuccessful initial treatments, he was treated with a combination of AmB-L (4 mg/kg) alternated with pentamidine (4 mg/kg) for 10 days but failed in the first therapeutic cycle. Subsequently, he had a good response to treatment with pentamidine (4 mg/kg).

6 February 2019
Verified
Book Chapter
Open access
PDF file
MLMayara Ingrid Sousa Lima
Mayara Ingrid Sousa Lima
EMEmilly Caroline dos Santos Moraes
Emilly Caroline dos Santos Moraes
JPJaqueline Diniz Pinho
Jaqueline Diniz Pinho
GSGustavo Henrique Corrêa Soares
Gustavo Henrique Corrêa Soares
ÍSÍtalo Vinícius Cantanhêde Santos
Ítalo Vinícius Cantanhêde Santos
Leprosy is a worldwide health problem, which needs the development of new and innovative strategies to be controlled. Early diagnosis of leprosy is an important contribution to reducing the incidence of the disease; thus, the development of biotechnology platforms, which include the mapping of antigens with potential to be used in immunodiagnostic and molecular methods for the detection of Mycobacterium leprae, is an important tool to confirm the clinical diagnostic. Molecular biology and biotechnological methods have been used to assist in the diagnosis of this disease, each one with its advantages and drawbacks. Enzyme-linked immunosorbent assay (ELISA) is the used method for leprosy diagnosis, and it allows the detection of infection-related antigens. Alternatively, due to their versatility to perform the same functions as the protein and non-protein natural antigens, mimetic peptides are considered an important tool. On the other hand, lateral flow assay (LFA) and optical and electrochemical biosensors are rapid and portable methods, capable of performing diagnosis in the field without sample preparation. This chapter presents such techniques, their uses in the diagnosis and detection of M. leprae, as well as the potential for the development of new techniques and strategies that can help to control and understand mycobacteriosis.